Human recombinant arginase I (Co)-PEG5000 [HuArgI (Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human glioblastoma cells

Journal of Neuro-Oncology

Volumn 122, Issue 1, 2015, Pages 75-85

  Khoury, Oula ^a   Ghazale, Noura ^a   Stone, Everett ^b   El Sibai, Mirvat ^a   Frankel, Arthur E ^c   Abi Habib, Ralph J ^a  

^a LEBANESE AMERICAN UNIVERSITY   (Lebanon)

^b The University of Texas at Austin   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Arginine; Autophagy; GBM; HuArgI (Co) PEG5000

Indexed keywords

ANTINEOPLASTIC AGENT; ARGINASE; ARGININE; ARGININOSUCCINATE SYNTHASE; CASPASE; CITRULLINE; LIPOCORTIN 5; PEGYLATED RECOMBINANT ARGINASE I COBALT; UNCLASSIFIED DRUG; ARGINASE I, HUMAN; HUARGI (CO)-PEG5000; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ARTICLE; AUTOPHAGY; AUXOTROPHY; CANCER CELL LINE; CELL DEATH; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY ASSAY; ENZYME ACTIVATION; GLIA CELL; GLIOBLASTOMA; GLIOMA CELL LINE; HUMAN; HUMAN CELL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; STAINING; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; FLOW CYTOMETRY; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; ARGINASE; ARGININE; ARGININOSUCCINATE SYNTHASE; AUTOPHAGY; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; FLOW CYTOMETRY; GLIOBLASTOMA; HUMANS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED;

EID: 84925490226     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1698-5     Document Type: Article

References (28)

1. American Cancer Society (2012) Cancer facts and figures 2012. American Cancer Society, Atlanta
2. Preusser M, de Ribaupierre S, Wohrer A, Erridge SC, Hegi M, Weller M, Stupp R (2011) Current concepts and management of glioblastoma. Ann Neurol 70:9–21
3. 2+ in human arginase I enhances cytotoxicity towards l-arginine auxotrophic cancer cell line. ACS Chem Biol 5:333–342
4. Morris SM Jr (2004) Enzymes of arginine metabolism. J Nutr 134:2743S–2747S
5. Kuo MT, Savaraj N, Feun LG (2010) Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes. Oncotarget 1:246–251
6. Muller HJ, Boos J (1998) Use of l-asparaginase in childhood ALL. Crit Rev Oncol Hematol 28:97–113
7. Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A et al (2005) Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 23:7660–7668
8. Cheng PN, Lam TL, Lam WM, Tsui SM, Cheng AW, Lo WH, Leumg YC (2007) Pegylated recombinant human arginase (rhArg-peg 5,000 mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res 67:309–317
9. Hernandez CP, Morrow K, Lopez-Barcons LA, Zabaleta J, Sierra R, Velasco C, Cole J, Rodriguez PC (2010) Pegylated arginase I: a potential therapeutic approach in T-ALL. Blood 115:5214–5221
10. Izzo F, Marra P, Beneduce G, Castello G, Vallone P, De Rosa V et al (2004) Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol 2:1815–1822
11. Lam TL, Wong GK, Chong HC, Cheng PN, Choi SC, Chow TL, Kwok SY, Poon RT, Wheatley DN, Lo WH, Leung YC (2009) Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest. Cancer Lett 277:91–100
12. Yoon CY, Shim YJ, Kim EH, Lee JH, Won NH, Kim JH, Park IS, Yoon DK, Min BH (2007) Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. Int J Cancer 120:897–905
13. Tanios R, Bekdash A, Kassab E, Stone E, Georgiou G, Frankel AE, Abi-Habib RJ (2013) Human recombinant arginase I(Co)-PEG5000 [HuArgI(Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human acute myeloid leukemia cells. Leuk Res 37(11):1565–1571
14. Glazer ES, Stone EM, Zhu C, Massey KL, Hamir AN, Curley SA (2012) Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts. Transl Oncol 4:138–146
15. Cheng PN, Wheatley DN (2008) Arginine deprivation addresses the Achilles Heel of Cancer: urea cycle deficiencies in melanoma, HCC and other cancers. Oncol News 2:6–8
16. Davis F (1978) Enzyme polyethylene glycol adducts: modified enzymes with unique properties. Enzyme Eng 4:169–173
17. Harris JM, Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2:214–221
18. Mauldin JP, Zeinali I, Kleypas K, Woo JH, Blackwood RS, Jo CH, Stone EM, Georgiou G, Frankel AE (2012) Recombinant human arginase toxicity in mice is reduced by citrulline supplementation. Transl Oncol 5:26–31
19. Abi-Habib RJ, Liu S, Bugge T, Leppla SH, Frankel AE (2004) A urokinase-activated recombinant diphtheria toxin targeting the granulocyte-macrophage colony-stimulating factor receptor is selectively cytotoxic to human acute myeloid leukemia blasts. Blood 104:2143–2148
20. Kassab E, Darwish M, Timsah Z, Liu SH, Leppla SH, Frankel AE, Abi-Habib RJ (2013) Cytotoxicity of anthrax lethal toxin to human acute myeloid leukemia cells is nonapoptotic and dependent on extracellular signal-regulated kinase 1/2 activity. Transl oncol 6:25–32
21. Kim RH, Coates JM, Bowles TL, McNerney GP, Sutcliffe J, Jung JU, Ghandour-Edwards R, Chuang FY, Bold RJ, Kung HJ (2009) Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res 69:700–708
22. Agrawal V, Woo JH, Borthakur G, Kantarjian H, Frankel AE (2013) Red blood cell-encapsulated l-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia. Protein Pept Lett 20:392–402
23. Agrawal V, Woo JH, Mauldin JP, Jo C, Stone EM, Georgiou G, Frankel AE (2012) Cytotoxicity of human recombinant arginase I (Co)-PEG5000 in the presence of supplemental l-citrulline is dependent on decreased argininosuccinate synthetase expression in human cells. Anticancer Drugs 23:51–64
24. Delage B, Fennell DA, Nicholson L, McNeish I, Lemoine NR, Crook T, Szlosarek PW (2010) Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer 126:2762–2772
25. Syed N, Langer J, Janczar K, Singh P, Lo Nigro C, Lattanzio L, Coley HM, Hatzimichael E, Bomalaski J, Szlosarek P, Awad M, O’Neil K, Roncaroli F, Crook T (2013) Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma. Cell Death Dis 4:e458
26. Periyasamy-Thandavan S, Jiang M, Schoenlein P, Dong Z (2009) Autophagy: molecular machinery, regulation, and implications for renal pathophysiology. Am J Physiol Renal Physiol 297:244–256
27. Wang J, Wu GS (2014) Role of autophagy in cisplatin resistance in ovarian cancer cells. J Biol Chem 289(24):17163–17173
28. Macintosh RL, Timpson P, Thorburn J, Anderson KI, Thorburn A, Ryan KM (2012) Inhibition of autophagy impairs tumor cell invasion in an organotypic model. Cell Cycle 11:2022–2029